Heidelberg Pharma AG, a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that the company’s shareholders approved the management proposals with a large majority (between 98.67% and 98.72%) at today’s ordinary virtual Annual General Meeting.
– All agenda items approved by a large majority
– 2026 Annual General Meeting elects Jack Yefei Ling as new member of the Supervisory Board